The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
MORPHO post hoc analysis: Association between MRD and RFS in patients with FLT3-ITD-mutated AML
Gilteritinib, a second-generation FLT3 inhibitor, demonstrated efficacy and tolerability as monotherapy in the phase III MORPHO trial (NCT02997202) in patients with FLT3-ITD-mutated AML (N = 356). The AML Hub previously reported on the key results and the impact of trial results on clinical practice. A post hoc analysis from this trial was published by Cortes, et al.1 in Blood, evaluating the association between MRD levels and the probability of RFS in patients with FLT3-ITD-mutated AML (n = 341).1
|
| Key learnings |
| More patients relapsed with pre-HCT MRD and post-HCT MRD vs U-MRD, in the placebo arm (39.2% and 51.3% vs 13.4%) and gilteritinib arm (17.7% and 21.9% vs 7.1%). |
| Increasing levels of MRD were correlated with a lower probability of RFS after HCT. The probabilities of survival at MRD0, MRD6, MRD5, and MRD4 were 82.92%, 73.68%, 56.25%, and 40.54%, respectively. |
| Patients with FLT3-ITD and D-MRD pre- or post-HCT had worse RFS rates than patients with U-MRD. 14.8% of participants had multiple FLT3-ITD clones detected as MRD and had worse survival irrespective of treatment arm. |
| These findings show that MRD levels correlate strongly with the probability of RFS. The FLT3-ITD MRD assay may identify which patients with AML could benefit from gilteritinib maintenance. |
Abbreviations: AML, acute myeloid leukemia; D-MRD, detectable measurable residual disease; HCT, hematopoietic stem cell transplantation; MRD0, no detectable MRD pre- or post-HCT; MRD6, mutant reads/total reads >10-6 but <10-5; MRD5, mutant reads/total reads >10-5 but <10-4; MRD4, mutant reads/total reads >10-4; RFS, relapse-free survival; U-MRD, undetectable MRD.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
